We’re thrilled to share that our CEO, キャロライン・シュライファー, has been quoted in ‘Labiotech’—One of Europe’s leading biotech news platforms!
の article explores how the U.S. tariff plans could impact the biopharma industry, with potential ripple effects across global supply chains and regulatory compliance.
“As a major supplier of critical pharmaceutical ingredients, China’s role in the supply chain is significant. Increased raw material costs are likely to trickle down the supply chain, raising overall production expenses,” said Caroline Shleifer, CEO of RegASK.
記事全文を読む here.
At RegASK, we help companies navigate shifting regulatory landscapes with AI-driven intelligence and expert insights—ensuring compliance, mitigating risks, and staying ahead of evolving trade policies.
